Concepedia

Sarah J. Schrieber

SJ

Statistics

Publications

17

Citations

1.2K

H-Index

12

Active since

2007

Affiliations

Center for Drug Evaluation and Research(Current)

United States Food and Drug Administration

Booz Allen Hamilton (United States)

Spaulding Clinical Research (United States)

University of North Carolina at Chapel Hill

Sarah J. Schrieber is an author at Center for Drug Evaluation and Research specializing in pharmacology, pharmacokinetics, and pharmacy.

ORCID

Publications per year

2007–2022

17

Publications

17

FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

Laleh Amiri‐Kordestani, Gideon M. Blumenthal, Qiang Xu et al. · Clinical Cancer Research · 2014 · 345 citations

, , +17

Pharmacokinetics and Metabolic Profile of Free, Conjugated, and Total Silymarin Flavonolignans in Human Plasma after Oral Administration of Milk Thistle Extract

Zhiming Wen, Todd Dumas, Sarah J. Schrieber et al. · Drug Metabolism and Disposition · 2007 · 171 citations

, , +13

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i> Mutation–Associated Advanced Ovarian Cancer

Sanjeeve Balasubramaniam, Julia A. Beaver, Sara Horton et al. · Clinical Cancer Research · 2017 · 164 citations

, , +17

Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis C

Roy L. Hawke, Sarah J. Schrieber, Tedi A. Soule et al. · The Journal of Clinical Pharmacology · 2009 · 141 citations · Full text

, , +15

The Pharmacokinetics of Silymarin Is Altered in Patients with Hepatitis C Virus and Nonalcoholic Fatty Liver Disease and Correlates with Plasma Caspase-3/7 Activity

Sarah J. Schrieber, Zhiming Wen, Manoli Vourvahis et al. · Drug Metabolism and Disposition · 2008 · 80 citations

, , +9

1–5 of 17